Evonik lays off 2,000 staffers; EurekaBio gets $40M for viral vector production; Sarepta unfazed by Novo-Catalent deal

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

Evonik has cut 2,000 staff mem­bers in the first phase of its “re­or­ga­ni­za­tion pro­gram,” ac­cord­ing to a com­pa­ny re­lease on Mon­day. The pro­gram, an­nounced last Sep­tem­ber, is set to de­fine the com­pa­ny’s new struc­ture and is an­tic­i­pat­ed to save around €400 mil­lion ($437 mil­lion) by the end of 2026.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.